1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Jeffrey Treiber: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Withdrawn | Jeffrey Treiber | 2024-07-15 | 2026-01-08 |
Central Nervous System Neoplasms (1) · Ependymoma (1) · Medulloblastoma (1)
Azacitidine (1) · Methotrexate (1) · Nivolumab (1)